A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics, safety and tolerability of
ABT-869 in Japanese patients with solid tumors up to the Recommended Phase Two Dose that was
determined in a previous the M04-710 study.